Sugi Predict

Sugi Predict / Compounds / SCHEMBL41728

SCHEMBL41728

SCHEMBL41728

O=C1CCCN1CCOc1ccc(Nc2nc3ccc(-c4cc(O)ccc4Cl)cn3n2)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 2/20 0.45
▸ SRC P12931 15/20 0.41
▸ PDGFRB P09619 3/20 0.39
▸ YES1 P07947 2/20 0.39
▸ LCK P06239 2/20 0.39
▸ CIT O14578 1/20 0.39
▸ GAK O14976 1/20 0.39
▸ EPHB6 O15197 1/20 0.39
▸ RIPK2 O43353 1/20 0.39
▸ PRKD3 O94806 1/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ RET P07949 1/20 0.39
▸ BCR P11274 1/20 0.39
▸ BRAF P15056 1/20 0.39
▸ EPHA2 P29317 1/20 0.39
▸ EPHB2 P29323 1/20 0.39
▸ TYK2 P29597 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ ACVR1B P36896 1/20 0.39
▸ TGFBR1 P36897 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL40869 0.89 SRC (0.52) SRCPDGFRBYES1LCKCIT
SCHEMBL42384 0.81 SRC (0.57) EGFRSRCPDGFRB
SCHEMBL612970 0.79 SRC (0.62) SRCPDGFRBYES1LCKCIT
SCHEMBL41896 0.78 SRC (0.48) SRCPDGFRBYES1LCKCIT
SCHEMBL42350 0.78 SRC (0.51) SRCPDGFRBYES1LCKCIT
SCHEMBL42778 0.77 LRRK2 (0.41) SRCPDGFRBYES1LCKCIT
SCHEMBL614557 0.77 SRC (0.63) SRCPDGFRBYES1LCKCIT
SCHEMBL612376 0.75 SRC (0.46) SRCPDGFRBYES1LCKCIT
SCHEMBL41603 0.75 SRC (0.63) SRCPDGFRBYES1LCKCIT
SCHEMBL615134 0.75 SRC (0.53) EGFRSRCPDGFRBYES1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130123271-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2013-05-16 — — US claimed
EP-2585439-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Fovea Pharmaceuticals (FR) 2013-05-01 — — EP claimed
WO-2011161159-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2011-12-29 — — WO claimed
US-20130123271-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2013-05-16 — — US disclosed
US-20130123271-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2013-05-16 — — US disclosed
EP-2585439-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Fovea Pharmaceuticals (FR) 2013-05-01 — — EP disclosed
WO-2011161159-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2011-12-29 — — WO disclosed
WO-2011161159-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2011-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123271-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION CAMK2D, CAMK2A, CAMK2B EGFR 966/4885SRC 401/4885PDGFRB 803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.